Czechia· CZ-0219152
NINLARO
A ixazomib product containing ixazomib citrate, registered in Czechia by Takeda Pharma A/S, Vallensbaek Strand. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Ixazomib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XG03 (ixazomib), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Ixazomib · ATC L01XG03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ixazomib costs, country by country.
Normalised to the WHO defined daily dose (0.43 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ixazomib · price per daily dose (0.43 mg)
USD · FX 28 Sept 2026
- CH Switzerland$395.98
The record
At a glance
SÚKL (Czech Republic)- Active substance
- IXAZOMIB CITRATE
- Manufacturer
- Takeda Pharma A/S, Vallensbaek Strand
- Country
- Czechia (CZ)
- ATC code
- L01XG03
- ATC class
- Ixazomib
- Defined daily dose
- 0.43 mg, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02191523(3X1)CZK 109221.63
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
226 interactions on record for ixazomib.
Graded by severity as the source publishes them — 45 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ixazomib · interactions on record
226 records
- 45 severe
- 181 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- RifampicinJ04AB02severe
- RifabutinJ04AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ixazomib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomIxazomib 3mg capsulesTakeda UK Ltd
- United StatesNINLAROTakeda Pharmaceuticals America, Inc.
- SwitzerlandNinlaro 3.0 mg, HartkapselnTakeda Pharma AG
- SpainNINLARO 3 MG CAPSULAS DURASTakeda Pharma A/S
- FinlandNINLAROTakeda Pharma A/S
- FranceNINLARO 3 mg, géluleTAKEDA PHARMA (DANEMARK)
- BelgiumNinlaro 3 mgTakeda Pharma
- IcelandNinlaroTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ninlaro
- Liechtenstein · Ninlaro
- Norway · Ninlaro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d662e52e-da62-43aa-b904-4c6b0702d8c2 GET /v1/drugs/d662e52e-da62-43aa-b904-4c6b0702d8c2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "CPS DUR",
"source": "sukl",
"strength": "3MG",
"pack_size": "3(3X1)",
"substance": "IXAZOMIB CITRATE",
"cz_kod_sukl": "0219152",
"product_type": "CH",
"substance_codes": "21098",
"registration_state": "R",
"registration_number": "EU/1/16/1094/002"
}See everything about ixazomib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.